Two Sigma Advisers LP Makes New $662,000 Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Two Sigma Advisers LP acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 49,700 shares of the company's stock, valued at approximately $662,000. Two Sigma Advisers LP owned approximately 0.19% of Eton Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ETON. Tower Research Capital LLC TRC bought a new stake in Eton Pharmaceuticals during the 4th quarter worth about $86,000. Jefferies Financial Group Inc. bought a new stake in Eton Pharmaceuticals during the 4th quarter worth about $133,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after acquiring an additional 1,634 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Eton Pharmaceuticals during the 4th quarter worth about $147,000. Finally, Bank of America Corp DE grew its holdings in Eton Pharmaceuticals by 5,422.4% during the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company's stock worth $148,000 after acquiring an additional 10,899 shares during the last quarter. Institutional investors own 27.86% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ETON shares. HC Wainwright reissued a "buy" rating and set a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, B. Riley reissued a "buy" rating and set a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded down $0.41 during trading hours on Friday, reaching $16.84. 404,191 shares of the company's stock traded hands, compared to its average volume of 214,015. The firm has a market capitalization of $451.62 million, a price-to-earnings ratio of -76.55 and a beta of 1.22. The firm's 50 day moving average is $16.24 and its 200-day moving average is $14.89. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. Analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.